Firefly Neuroscience (NASDAQ: AIFF) announced a new partnership with HealingMaps the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (TMS) clinics, and Advanced Behavioral Strategies (ABS).
The collaboration follows the HealingMaps and Capstone Management Group announcement of their official launch of the Healing Health Alliance—the first-of-its-kind Group Purchasing Organization (GPO) dedicated to supporting ketamine clinics, psilocybin retreats, TMS clinics, and more. It will provide HealingMaps’ large and growing provider network with one-stop purchasing and preferred pricing for Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain health analytics platform.
Firefly’s platform replaces the patient-reported questionnaires or subjective assessments that most clinics today use to guide treatment and measure success. The company’s simple, non-invasive EEG assessment uses AI to analyze brain activity across multiple regions, comparing patient data against Firefly’s proprietary database—the world’s largest known normative EEG/ERP data repository.
Key benefits for clinics include:
- Objective, FDA-cleared analytics: standardized brain health insights that complement ketamine, psilocybin, and TMS treatment models.
- Demonstrated outcomes: providers can show patients measurable brain health changes correlated to treatment.
- Improved patient confidence: objective data builds trust, enhances transparency, and supports long-term care engagement.
In a statement, Greg Lipschitz, CEO of Firefly, commented, “Firefly’s mission is to harness the power of AI and EEG to transform brain health. By partnering with HealingMaps, we are significantly expanding access to our FDA-cleared brain analytics platform, empowering ketamine, psilocybin, and TMS clinics to strengthen care, prove outcomes, and grow sustainable new revenue streams.”
Cory Jones, co-founder of HealingMaps, added, “HealingMaps exists to connect patients with trusted, innovative providers. Partnering with Firefly means our provider network can now access unique, objective brain health analytics that provide evidence-based outcome analyses and potential new revenue opportunities, while giving patients greater confidence in their care.”
